<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33658617</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2399-3642</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>4</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
              <Day>03</Day>
            </PubDate>
          </JournalIssue>
          <Title>Communications biology</Title>
          <ISOAbbreviation>Commun Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Enhanced antitumoral activity of TLR7 agonists via activation of human endogenous retroviruses by HDAC inhibitors.</ArticleTitle>
        <Pagination>
          <StartPage>276</StartPage>
          <MedlinePgn>276</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">276</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s42003-021-01800-3</ELocationID>
        <Abstract>
          <AbstractText>In this work, we are reporting that "Shock and Kill", a therapeutic approach designed to eliminate latent HIV from cell reservoirs, is extrapolatable to cancer therapy. This is based on the observation that malignant cells express a spectrum of human endogenous retroviral elements (HERVs) which can be transcriptionally boosted by HDAC inhibitors. The endoretroviral gene HERV-V2 codes for an envelope protein, which resembles syncytins. It is significantly overexpressed upon exposure to HDAC inhibitors and can be effectively targeted by simultaneous application of TLR7/8 agonists, triggering intrinsic apoptosis. We demonstrated that this synergistic cytotoxic effect was accompanied by the functional disruption of the TLR7/8-NFκB, Akt/PKB, and Ras-MEK-ERK signalling pathways. CRISPR/Cas9 ablation of TLR7 and HERV-V1/V2 curtailed apoptosis significantly, proving the pivotal role of these elements in driving cell death. The effectiveness of this new approach was confirmed in ovarian tumour xenograft studies, revealing a promising avenue for future cancer therapies.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Díaz-Carballo</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Ruhr University Bochum, Faculty of Medicine, Department of Haematology and Oncology, Institute of Molecular Oncology and Experimental Therapeutics, Marien Hospital Herne, Herne, Germany. david.diaz-carballo@marienhospital-herne.de.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saka</LastName>
            <ForeName>Sahitya</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-6446-4611</Identifier>
            <AffiliationInfo>
              <Affiliation>Ruhr University Bochum, Faculty of Medicine, Department of Haematology and Oncology, Institute of Molecular Oncology and Experimental Therapeutics, Marien Hospital Herne, Herne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Acikelli</LastName>
            <ForeName>Ali H</ForeName>
            <Initials>AH</Initials>
            <Identifier Source="ORCID">0000-0002-7575-4152</Identifier>
            <AffiliationInfo>
              <Affiliation>Ruhr University Bochum, Faculty of Medicine, Department of Haematology and Oncology, Institute of Molecular Oncology and Experimental Therapeutics, Marien Hospital Herne, Herne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Homp</LastName>
            <ForeName>Ekaterina</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Ruhr University Bochum, Faculty of Medicine, Department of Haematology and Oncology, Institute of Molecular Oncology and Experimental Therapeutics, Marien Hospital Herne, Herne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Erwes</LastName>
            <ForeName>Julia</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Ruhr University Bochum, Faculty of Medicine, Department of Haematology and Oncology, Institute of Molecular Oncology and Experimental Therapeutics, Marien Hospital Herne, Herne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Demmig</LastName>
            <ForeName>Rebecca</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Ruhr University Bochum, Faculty of Medicine, Department of Haematology and Oncology, Institute of Molecular Oncology and Experimental Therapeutics, Marien Hospital Herne, Herne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klein</LastName>
            <ForeName>Jacqueline</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0003-2993-3077</Identifier>
            <AffiliationInfo>
              <Affiliation>Ruhr University Bochum, Faculty of Medicine, Department of Haematology and Oncology, Institute of Molecular Oncology and Experimental Therapeutics, Marien Hospital Herne, Herne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schröer</LastName>
            <ForeName>Katrin</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0003-2242-2450</Identifier>
            <AffiliationInfo>
              <Affiliation>Ruhr University Bochum, Faculty of Medicine, Department of Haematology and Oncology, Institute of Molecular Oncology and Experimental Therapeutics, Marien Hospital Herne, Herne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Malak</LastName>
            <ForeName>Sascha</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Ruhr University Bochum, Faculty of Medicine, Department of Haematology and Oncology, Institute of Molecular Oncology and Experimental Therapeutics, Marien Hospital Herne, Herne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>D'Souza</LastName>
            <ForeName>Flevy</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Ruhr University Bochum, Faculty of Medicine, Department of Haematology and Oncology, Institute of Molecular Oncology and Experimental Therapeutics, Marien Hospital Herne, Herne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Noa-Bolaño</LastName>
            <ForeName>Adrien</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-5744-3174</Identifier>
            <AffiliationInfo>
              <Affiliation>Ruhr University Bochum, Faculty of Medicine, Department of Haematology and Oncology, Institute of Molecular Oncology and Experimental Therapeutics, Marien Hospital Herne, Herne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Menze</LastName>
            <ForeName>Saskia</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Ruhr University Bochum, Faculty of Medicine, Department of Haematology and Oncology, Institute of Molecular Oncology and Experimental Therapeutics, Marien Hospital Herne, Herne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pano</LastName>
            <ForeName>Emilio</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0002-5633-2982</Identifier>
            <AffiliationInfo>
              <Affiliation>Ruhr University Bochum, Faculty of Medicine, Department of Haematology and Oncology, Institute of Molecular Oncology and Experimental Therapeutics, Marien Hospital Herne, Herne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Andrioff</LastName>
            <ForeName>Swetlana</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-3098-5520</Identifier>
            <AffiliationInfo>
              <Affiliation>Ruhr University Bochum, Faculty of Medicine, Department of Haematology and Oncology, Institute of Molecular Oncology and Experimental Therapeutics, Marien Hospital Herne, Herne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Teipel</LastName>
            <ForeName>Marc</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Ruhr University Bochum, Faculty of Medicine, Department of Haematology and Oncology, Institute of Molecular Oncology and Experimental Therapeutics, Marien Hospital Herne, Herne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dammann</LastName>
            <ForeName>Philip</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Central Animal Laboratory, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klein</LastName>
            <ForeName>Diana</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0002-1770-443X</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Cell Biology, Cancer Research, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nasreen</LastName>
            <ForeName>Amber</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Visceral Surgery Department, Marien Hospital Herne, Ruhr University Bochum Medical School, Herne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tannapfel</LastName>
            <ForeName>Andrea</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pathology, Ruhr University Bochum, Bochum, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grandi</LastName>
            <ForeName>Nicole</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Life and Environmental Sciences, University of Cagliari, Cittadella Universitaria di Monserrato, Monserrato, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tramontano</LastName>
            <ForeName>Enzo</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Life and Environmental Sciences, University of Cagliari, Cittadella Universitaria di Monserrato, Monserrato, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ochsenfarth</LastName>
            <ForeName>Crista</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-5744-8661</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesia, Intensive Care, Pain and Palliative Medicine, Marien Hospital Herne, Ruhr-University Bochum Medical School, Herne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Strumberg</LastName>
            <ForeName>Dirk</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Ruhr University Bochum, Faculty of Medicine, Department of Haematology and Oncology, Institute of Molecular Oncology and Experimental Therapeutics, Marien Hospital Herne, Herne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>03</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Commun Biol</MedlineTA>
        <NlmUniqueID>101719179</NlmUniqueID>
        <ISSNLinking>2399-3642</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047630">Depsipeptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D056572">Histone Deacetylase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011621">Pteridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051199">Toll-Like Receptor 7</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>58IFB293JI</RegistryNumber>
          <NameOfSubstance UI="D000077337">Vorinostat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>CX3T89XQBK</RegistryNumber>
          <NameOfSubstance UI="C087123">romidepsin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>O8M467C50G</RegistryNumber>
          <NameOfSubstance UI="C582524">vesatolimod</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>P1QW714R7M</RegistryNumber>
          <NameOfSubstance UI="D000077271">Imiquimod</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047630" MajorTopicYN="N">Depsipeptides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020077" MajorTopicYN="N">Endogenous Retroviruses</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056572" MajorTopicYN="N">Histone Deacetylase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077271" MajorTopicYN="N">Imiquimod</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011621" MajorTopicYN="N">Pteridines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051199" MajorTopicYN="N">Toll-Like Receptor 7</DescriptorName>
          <QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014775" MajorTopicYN="N">Virus Activation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077337" MajorTopicYN="N">Vorinostat</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>4</Day>
          <Hour>5</Hour>
          <Minute>49</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33658617</ArticleId>
        <ArticleId IdType="pmc">PMC7930250</ArticleId>
        <ArticleId IdType="doi">10.1038/s42003-021-01800-3</ArticleId>
        <ArticleId IdType="pii">10.1038/s42003-021-01800-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34:637–650. doi: 10.1016/j.immuni.2011.05.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2011.05.006</ArticleId>
            <ArticleId IdType="pubmed">21616434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forsbach A, et al.  Dual or triple activation of TLR7, TLR8, and/or TLR9 by single-stranded oligoribonucleotides. Nucleic Acid. Ther. 2011;21:423–436. doi: 10.1089/nat.2011.0323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/nat.2011.0323</ArticleId>
            <ArticleId IdType="pubmed">22196370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawai T, Akira S. Signaling to NF-κB by Toll-like receptors. Trends Mol. Med. 2007;13:460–469. doi: 10.1016/j.molmed.2007.09.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molmed.2007.09.002</ArticleId>
            <ArticleId IdType="pubmed">18029230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taniguchi K, Karin M. NF-κB, inflammation, immunity and cancer. Coming of age. Nat. Rev. Immunol. 2018;18:309–324. doi: 10.1038/nri.2017.142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri.2017.142</ArticleId>
            <ArticleId IdType="pubmed">29379212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brücher BL, Lang F, Jamall IS, Bandapalli OR. NF-κB signaling and crosstalk during carcinogenesis. 4open. 2019;2:13. doi: 10.1051/fopen/2019010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1051/fopen/2019010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parker LC, Prince LR, Sabroe I. Translational mini-review series on Toll-like receptors. Networks regulated by Toll-like receptors mediate innate and adaptive immunity. Clin. Exp. Immunol. 2007;147:199–207. doi: 10.1111/j.1365-2249.2006.03203.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2249.2006.03203.x</ArticleId>
            <ArticleId IdType="pmc">PMC1810480</ArticleId>
            <ArticleId IdType="pubmed">17223959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rebbapragada I, et al.  Molecular determinants of GS-9620-dependent TLR7 activation. PLoS ONE. 2016;11:e0146835. doi: 10.1371/journal.pone.0146835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0146835</ArticleId>
            <ArticleId IdType="pmc">PMC4718629</ArticleId>
            <ArticleId IdType="pubmed">26784926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geller MA, et al.  Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol. immunother. 2010;59:1877–1884. doi: 10.1007/s00262-010-0914-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-010-0914-1</ArticleId>
            <ArticleId IdType="pmc">PMC4098785</ArticleId>
            <ArticleId IdType="pubmed">20820775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee, S.-W. et al. The expression and function of toll-like receptors (TLRs) in ovarian cancer cell lines. J. Immunother. Cancer3, 10.1186/2051-1426-ro3-S2-P76 (2015).</Citation>
        </Reference>
        <Reference>
          <Citation>Ahn M-Y, et al.  Toll-like receptor 7 agonist, imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis. J. Oral. Pathol. Med. 2012;41:540–546.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22577802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chi H, et al.  Anti-tumor activity of Toll-like receptor 7 agonists. Front. Pharmacol. 2017;8:304. doi: 10.3389/fphar.2017.00304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2017.00304</ArticleId>
            <ArticleId IdType="pmc">PMC5450331</ArticleId>
            <ArticleId IdType="pubmed">28620298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kassiotis G. Endogenous retroviruses and the development of cancer. J. Immunol. 2014;192:1343–1349. doi: 10.4049/jimmunol.1302972.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1302972</ArticleId>
            <ArticleId IdType="pmc">PMC3925786</ArticleId>
            <ArticleId IdType="pubmed">24511094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romanish MT, Cohen CJ, Mager DL. Potential mechanisms of endogenous retroviral-mediated genomic instability in human cancer. Semin. Cancer Biol. 2010;20:246–253. doi: 10.1016/j.semcancer.2010.05.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcancer.2010.05.005</ArticleId>
            <ArticleId IdType="pubmed">20685251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonner TI, O’Connell C, Cohen M. Cloned endogenous retroviral sequences from human DNA. Proc. Natl Acad. Sci. USA. 1982;79:4709–4713. doi: 10.1073/pnas.79.15.4709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.79.15.4709</ArticleId>
            <ArticleId IdType="pmc">PMC346746</ArticleId>
            <ArticleId IdType="pubmed">6181510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kassiotis, G. &amp; Stoye, J. P. Making a virtue of necessity. The pleiotropic role of human endogenous retroviruses in cancer. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 372, 10.1098/rstb.2016.0277 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5597744</ArticleId>
            <ArticleId IdType="pubmed">28893944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee YN, Bieniasz PD. Reconstitution of an infectious human endogenous retrovirus. PLoS Pathog. 2007;3:e10. doi: 10.1371/journal.ppat.0030010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.0030010</ArticleId>
            <ArticleId IdType="pmc">PMC1781480</ArticleId>
            <ArticleId IdType="pubmed">17257061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurth R, Bannert N. Beneficial and detrimental effects of human endogenous retroviruses. Int. J. Cancer. 2010;126:306–314. doi: 10.1002/ijc.24902.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.24902</ArticleId>
            <ArticleId IdType="pubmed">19795446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vargiu L, et al.  Classification and characterization of human endogenous retroviruses; mosaic forms are common. Retrovirology. 2016;13:253. doi: 10.1186/s12977-015-0232-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12977-015-0232-y</ArticleId>
            <ArticleId IdType="pmc">PMC4724089</ArticleId>
            <ArticleId IdType="pubmed">26800882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Díaz-Carballo D, et al.  A distinct oncogenerative multinucleated cancer cell serves as a source of stemness and tumor heterogeneity. Cancer Res. 2018;78:2318–2331. doi: 10.1158/0008-5472.CAN-17-1861.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-17-1861</ArticleId>
            <ArticleId IdType="pubmed">29440172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grandi N, Tramontano E. Human endogenous retroviruses are ancient acquired elements still shaping innate immune responses. Front. Immunol. 2018;9:860. doi: 10.3389/fimmu.2018.02039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.02039</ArticleId>
            <ArticleId IdType="pmc">PMC6139349</ArticleId>
            <ArticleId IdType="pubmed">30250470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grandi N, Tramontano E. HERV envelope proteins. physiological role and pathogenic potential in cancer and autoimmunity. Front. Microbiol. 2018;9:220. doi: 10.3389/fmicb.2018.00462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmicb.2018.00462</ArticleId>
            <ArticleId IdType="pmc">PMC5861771</ArticleId>
            <ArticleId IdType="pubmed">29593697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kjeldbjerg AL, Villesen P, Aagaard L, Pedersen FS. Gene conversion and purifying selection of a placenta-specific ERV-V envelope gene during simian evolution. BMC Evol. Biol. 2008;8:266. doi: 10.1186/1471-2148-8-266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2148-8-266</ArticleId>
            <ArticleId IdType="pmc">PMC2567338</ArticleId>
            <ArticleId IdType="pubmed">18826608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esnault C, Cornelis G, Heidmann O, Heidmann T. Differential evolutionary fate of an ancestral primate endogenous retrovirus envelope gene, the EnvV syncytin, captured for a function in placentation. PLoS Genet. 2013;9:e1003400. doi: 10.1371/journal.pgen.1003400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pgen.1003400</ArticleId>
            <ArticleId IdType="pmc">PMC3610889</ArticleId>
            <ArticleId IdType="pubmed">23555306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Divsalar DN, et al.  Novel histone deacetylase inhibitors and HIV-1 latency-reversing agents identified by large-scale virtual screening. Front. Pharmacol. 2020;11:19. doi: 10.3389/fphar.2020.00905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2020.00905</ArticleId>
            <ArticleId IdType="pmc">PMC7311767</ArticleId>
            <ArticleId IdType="pubmed">32625097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deeks SG. Shock and kill. Nature. 2012;487:439–440. doi: 10.1038/487439a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/487439a</ArticleId>
            <ArticleId IdType="pubmed">22836995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lichterfeld M. Reactivation of latent HIV moves shock-and-kill treatments forward. Nature. 2020;578:42–43. doi: 10.1038/d41586-020-00010-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/d41586-020-00010-x</ArticleId>
            <ArticleId IdType="pubmed">32020104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hurst T, et al.  Human endogenous retrovirus (HERV) expression is not induced by treatment with the histone deacetylase (HDAC) inhibitors in cellular models of HIV-1 latency. Retrovirology. 2016;13:10. doi: 10.1186/s12977-016-0242-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12977-016-0242-4</ArticleId>
            <ArticleId IdType="pmc">PMC4744380</ArticleId>
            <ArticleId IdType="pubmed">26852322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janumyan YM, et al.  Bcl-xL/Bcl-2 coordinately regulates apoptosis, cell cycle arrest and cell cycle entry. EMBO J. 2003;22:5459–5470. doi: 10.1093/emboj/cdg533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/emboj/cdg533</ArticleId>
            <ArticleId IdType="pmc">PMC213787</ArticleId>
            <ArticleId IdType="pubmed">14532118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch. 2005;446:475–482. doi: 10.1007/s00428-005-1264-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00428-005-1264-9</ArticleId>
            <ArticleId IdType="pubmed">15856292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mukherjee P, et al.  SARM1, not MyD88, mediates TLR7/TLR9-induced apoptosis in neurons. J. Immunol. 2015;195:4913–4921. doi: 10.4049/jimmunol.1500953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1500953</ArticleId>
            <ArticleId IdType="pmc">PMC4769638</ArticleId>
            <ArticleId IdType="pubmed">26423149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabellini C, et al.  Involvement of nuclear factor-κ B in bcl-xL-induced interleukin 8 expression in glioblastoma. J. Neurochem. 2008;107:871–882. doi: 10.1111/j.1471-4159.2008.05661.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-4159.2008.05661.x</ArticleId>
            <ArticleId IdType="pubmed">18786178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoffmann, E., Dittrich-Breiholz, O., Holtmann, H. &amp; Kracht, M. Multiple control of interleukin-8 gene expression. J. Leukoc. Biol. 72, 847–855 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12429706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bai D, Ueno L, Vogt PK. Akt-mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and Akt. Int. J. Cancer. 2009;125:2863–2870. doi: 10.1002/ijc.24748.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.24748</ArticleId>
            <ArticleId IdType="pmc">PMC2767458</ArticleId>
            <ArticleId IdType="pubmed">19609947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>King CC, et al.  The rate of NF-κB nuclear translocation is regulated by PKA and A kinase interacting protein 1. PLoS ONE. 2011;6:e18713. doi: 10.1371/journal.pone.0018713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0018713</ArticleId>
            <ArticleId IdType="pmc">PMC3083391</ArticleId>
            <ArticleId IdType="pubmed">21556136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lemaître C, Tsang J, Bireau C, Heidmann T, Dewannieux M. A human endogenous retrovirus-derived gene that can contribute to oncogenesis by activating the ERK pathway and inducing migration and invasion. PLoS Pathog. 2017;13:e1006451. doi: 10.1371/journal.ppat.1006451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1006451</ArticleId>
            <ArticleId IdType="pmc">PMC5501692</ArticleId>
            <ArticleId IdType="pubmed">28651004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hurst TP, Magiorkinis G. Activation of the innate immune response by endogenous retroviruses. J. Gen. Virol. 2015;96:1207–1218. doi: 10.1099/vir.0.000017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1099/vir.0.000017</ArticleId>
            <ArticleId IdType="pubmed">26068187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors. the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23:165–175. doi: 10.1016/j.immuni.2005.06.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2005.06.008</ArticleId>
            <ArticleId IdType="pubmed">16111635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bubna A. Vorinostat—an overview. Indian J. Dermatol. 2015;60:419. doi: 10.4103/0019-5154.160511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/0019-5154.160511</ArticleId>
            <ArticleId IdType="pmc">PMC4533557</ArticleId>
            <ArticleId IdType="pubmed">26288427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valdez BC, et al.  Romidepsin targets multiple survival signaling pathways in malignant T cells. Blood Cancer J. 2015;5:e357–e357. doi: 10.1038/bcj.2015.83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bcj.2015.83</ArticleId>
            <ArticleId IdType="pmc">PMC4635192</ArticleId>
            <ArticleId IdType="pubmed">26473529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Søgaard OS, et al.  The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog. 2015;11:e1005142. doi: 10.1371/journal.ppat.1005142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1005142</ArticleId>
            <ArticleId IdType="pmc">PMC4575032</ArticleId>
            <ArticleId IdType="pubmed">26379282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jern P, Lindeskog M, Karlsson D, Blomberg J. Full-length HERV-H elements with env SU open reading frames in the human genome. AIDS Res. Hum. Retroviruses. 2002;18:671–676. doi: 10.1089/088922202760019383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/088922202760019383</ArticleId>
            <ArticleId IdType="pubmed">12079564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Revathidevi S, Munirajan AK. Akt in cancer. Mediator and more. Semin. Cancer Biol. 2019;59:80–91. doi: 10.1016/j.semcancer.2019.06.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcancer.2019.06.002</ArticleId>
            <ArticleId IdType="pubmed">31173856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shrum CK, DeFrancisco D, Meffert MK. Stimulated nuclear translocation of NF-κB and shuttling differentially depend on dynein and the dynactin complex. Proc. Natl Acad. Sci. USA. 2009;106:2647–2652. doi: 10.1073/pnas.0806677106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0806677106</ArticleId>
            <ArticleId IdType="pmc">PMC2650318</ArticleId>
            <ArticleId IdType="pubmed">19196984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller DM, Thomas SD, Islam A, Muench D, Sedoris K. c-Myc and cancer metabolism. Clin. Cancer Res. 2012;18:5546–5553. doi: 10.1158/1078-0432.CCR-12-0977.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-12-0977</ArticleId>
            <ArticleId IdType="pmc">PMC3505847</ArticleId>
            <ArticleId IdType="pubmed">23071356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bakouny Z, Choueiri TK. IL-8 and cancer prognosis on immunotherapy. Nat. Med. 2020;26:650–651. doi: 10.1038/s41591-020-0873-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-020-0873-9</ArticleId>
            <ArticleId IdType="pubmed">32405061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee L-F, et al.  IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J. I. 2000;164:2769–2775.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10679119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Josephs SF, et al.  Unleashing endogenous TNF-alpha as a cancer immunotherapeutic. J. Transl. Med. 2018;16:389. doi: 10.1186/s12967-018-1611-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12967-018-1611-7</ArticleId>
            <ArticleId IdType="pmc">PMC6119315</ArticleId>
            <ArticleId IdType="pubmed">30170620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Franco S, Turdo A, Todaro M, Stassi G. Role of type I and II interferons in colorectal cancer and melanoma. Front. Immunol. 2017;8:878. doi: 10.3389/fimmu.2017.00878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2017.00878</ArticleId>
            <ArticleId IdType="pmc">PMC5526853</ArticleId>
            <ArticleId IdType="pubmed">28798748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ni L, Lu J. Interferon gamma in cancer immunotherapy. Cancer Med. 2018;7:4509–4516. doi: 10.1002/cam4.1700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cam4.1700</ArticleId>
            <ArticleId IdType="pmc">PMC6143921</ArticleId>
            <ArticleId IdType="pubmed">30039553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mojic, M., Takeda, K. &amp; Hayakawa, Y. The dark side of IFN-γ. Its role in promoting cancer immunoevasion. Int. J. Mol. Sci.19, 10.3390/ijms19010089 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5796039</ArticleId>
            <ArticleId IdType="pubmed">29283429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis. Mechanistic description of dead and dying eukaryotic cells. Infect. Immun. 2005;73:1907–1916. doi: 10.1128/IAI.73.4.1907-1916.2005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.73.4.1907-1916.2005</ArticleId>
            <ArticleId IdType="pmc">PMC1087413</ArticleId>
            <ArticleId IdType="pubmed">15784530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Díaz-Carballo D, et al.  Therapeutic potential of antiviral drugs targeting chemorefractory colorectal adenocarcinoma cells overexpressing endogenous retroviral elements. J. Exp. Clin. Cancer Res. 2015;34:81. doi: 10.1186/s13046-015-0199-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-015-0199-5</ArticleId>
            <ArticleId IdType="pmc">PMC4542094</ArticleId>
            <ArticleId IdType="pubmed">26260344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodea-Palomares I, González-Pleiter M, Martín-Betancor K, Rosal R, Fernández-Piñas F. Additivity and interactions in ecotoxicity of pollutant mixtures. some patterns, conclusions, and open questions. Toxics. 2015;3:342–369. doi: 10.3390/toxics3040342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxics3040342</ArticleId>
            <ArticleId IdType="pmc">PMC5606646</ArticleId>
            <ArticleId IdType="pubmed">29051468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furey TS. ChIP–seq and beyond. New and improved methodologies to detect and characterize protein–DNA interactions. Nat. Rev. Genet. 2012;13:840–852. doi: 10.1038/nrg3306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrg3306</ArticleId>
            <ArticleId IdType="pmc">PMC3591838</ArticleId>
            <ArticleId IdType="pubmed">23090257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grandi N, et al.  Identification of a novel HERV-K(HML10). Comprehensive characterization and comparative analysis in non-human primates provide insights about HML10 proviruses structure and diffusion. Mob. DNA. 2017;8:15. doi: 10.1186/s13100-017-0099-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13100-017-0099-7</ArticleId>
            <ArticleId IdType="pmc">PMC5667498</ArticleId>
            <ArticleId IdType="pubmed">29118853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grandi N, Cadeddu M, Blomberg J, Tramontano E. Contribution of type W human endogenous retroviruses to the human genome. Characterization of HERV-W proviral insertions and processed pseudogenes. Retrovirology. 2016;13:67. doi: 10.1186/s12977-016-0301-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12977-016-0301-x</ArticleId>
            <ArticleId IdType="pmc">PMC5016936</ArticleId>
            <ArticleId IdType="pubmed">27613107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pisano, M. P., Grandi, N., Cadeddu, M., Blomberg, J. &amp; Tramontano, E. Comprehensive characterization of the human endogenous retrovirus HERV-K(HML-6) group. Overview of structure, phylogeny, and contribution to the human genome. J. Virol.93, 10.1128/JVI.00110-19 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6675890</ArticleId>
            <ArticleId IdType="pubmed">31167914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ketteler J, et al.  Caveolin-1 regulates the ASMase/ceramide-mediated radiation response of endothelial cells in the context of tumor-stroma interactions. Cell Death Dis. 2020;11:228. doi: 10.1038/s41419-020-2418-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-020-2418-z</ArticleId>
            <ArticleId IdType="pmc">PMC7145831</ArticleId>
            <ArticleId IdType="pubmed">32273493</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
